XML 91 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaborative Arrangements - Financial Information (Details) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]   Sales    
Sales   $ 60,115 $ 59,283 $ 48,704
Cost of sales   16,126 17,411 13,626
Selling, general and administrative   10,504 10,042 9,634
Research and development   30,531 13,548 12,245
Receivables included in Other current assets   32,168 35,722  
Payables included in Accrued and other current liabilities   15,766 14,159  
Amortization expense for intangible assets   2,000 2,100 1,600
AstraZeneca        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Amortization expense for intangible assets     250  
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue from collaborative arrangement   1,296 1,170 1,018
Cost of sales   311 492 167
Selling, general and administrative   192 185 178
Research and development   79 106 120
Receivables included in Other current assets   341 303  
Payables included in Accrued and other current liabilities   256 123  
Payables included in Other Noncurrent Liabilities   600 600  
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Alliance revenue - Lynparza        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue from collaborative arrangement   1,199 1,116 989
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Alliance revenue - Koselugo        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue from collaborative arrangement   97 54 29
Eisai        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Amortization expense for intangible assets   154    
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue from collaborative arrangement   960 876 704
Cost of sales   381 212 195
Selling, general and administrative   189 158 127
Research and development   66 136 173
Receivables included in Other current assets   226 214  
Payables included in Accrued and other current liabilities   125 0  
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue from collaborative arrangement   367 341 342
Sales   658 601 601
Cost of sales   224 210 424
Selling, general and administrative   131 153 126
Research and development   90 75 53
Receivables included in Other current assets   156 143  
Payables included in Accrued and other current liabilities   80 80  
Amortization expense for intangible assets       153
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Adempas        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales   255 238 252
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Verquvo        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales   36 22 7
Ridgeback Biotherapeutics LP | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Cost of sales   852 3,038 502
Selling, general and administrative   97 147 37
Research and development   60 88 137
Payables included in Accrued and other current liabilities   113 348  
Ridgeback Biotherapeutics LP | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lagevrio        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales   1,428 5,684 $ 952
Moderna | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Selling, general and administrative   5 0  
Research and development   218 288  
Payables included in Accrued and other current liabilities   $ 63 7  
Contractual payment $ 250   $ 250